MedTrace Logo

Growth Hormone for Osteoporosis Pseudoglioma Syndrome

NCT01614171 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-04-08

No results posted yet for this study

Summary

Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of childhood osteoporosis and congenital blindness for which new treatments are needed. We have found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that growth hormone therapy will improve muscle mass and bone strength in OPPG.

Conditions

  • Osteoporosis Pseudoglioma Syndrome

Interventions

BIOLOGICAL

Human recombinant growth hormone

growth hormone treatment for 6 months (daily, weight based)

Sponsors & Collaborators

Principal Investigators

  • Elizabeth A Streeten, MD · University of Maryland School of Medicine, Division of Endocrinology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01614171 on ClinicalTrials.gov